Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
4.72
Oct 23 • 3:59 PM ET Dollar change-0.04 Percentage change(-0.84%)
Aftermarket Close
4.72
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
65.70M
Enterprise Value
72.88M
Income
-1.10M
Sales
60.66M
Book/sh
0.28
Cash/sh
0.31
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
214
IPO
Jun 15, 1992
P/E
-
Forward P/E
-
PEG
-
P/S
1.08
P/B
16.88
P/C
15.07
P/FCF
-
EV/EBITDA
202.45
EV/Sales
1.20
Quick Ratio
1.03
Current Ratio
1.03
Debt/Eq
2.82
LT Debt/Eq
2.60
Option/Short
Yes / Yes
EPS (ttm)
-0.08
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
40.02% -
Sales past 3/5Y
3.33% 7.68%
EPS Y/Y TTM
-136.61%
Sales Y/Y TTM
6.65%
EPS Q/Q
3.16%
Sales Q/Q
8.84%
Insider Own
56.62%
Insider Trans
0.00%
Inst Own
18.81%
Inst Trans
-46.75%
ROA
-3.46%
ROE
-29.83%
ROIC
-7.89%
Gross Margin
47.69%
Oper. Margin
-1.54%
Profit Margin
-1.82%
SMA20
-2.88%
SMA50
-5.08%
SMA200
-18.56%
Trades
Shs Outstand
13.92M
Shs Float
6.04M
52W High
8.31 -43.20%
52W Low
4.59 2.83%
Volatility
4.63% 3.66%
ATR (14)
0.21
RSI (14)
42.05
Beta
0.48
Rel Volume
0.33
Avg Volume
11.10K
Volume
3,677
Perf Week
0.43%
Perf Month
-4.65%
Perf Quarter
-22.11%
Perf Half Y
-19.52%
Perf YTD
-31.69%
Perf Year
-30.07%
Perf 3Y
-26.37%
Perf 5Y
-52.66%
Perf 10Y
189.57%
Prev Close
4.76
Price
4.72
Change %
-0.84%
Date Action Analyst Rating Change Price Target Change
Sep-12-24Upgrade Craig Hallum Hold → Buy $6
Nov-18-19Initiated The Benchmark Company Speculative Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ACKERMAN JOELDirectorOct 15 '26Option Exercise1.6069,794111,6701,126,333Oct 16 12:45 PM
ACKERMAN JOELDirectorOct 30 '25Option Exercise2.1094,405198,2501,056,539Nov 06 11:19 AM
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Executive ChairDr. Ronnie Morris M.D.
CEO & DirectorMr. Robert Brainin
Chief Financial OfficerMr. David Barry Miller M.B.A.
Chief Operating OfficerDr. Maria Mancini Ph.D.
Executive Vice President of GrowthDr. Marianna Zipeto Ph.D.